[Implications of the formulation of m-tyrosine from DOPA for Parkinsonism].
D000818:Animals; D002395:Catecholamines / Q000037:antagonists & inhibitors; D002628:Chemoreceptor Cells / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism* / Q000494:pharmacology
D002395:Catecholamines; D014443:Tyrosine; D004295:Dihydroxyphenylalanine
Implicaties van ce vorming van m-tyrosine uit DOPA voor de ziekte van Parkinson